Protective Effects of Salvianolate on Myocardial Injury or Myocardial Infarction after Elective Percutaneous Coronary Intervention in NSTE-ACS Patients: A Randomized Placebo-Controlled Trial

Autor: Yang Ou, Yun-Zhi Shen, Hong-Ying Liu, Xinping Luo, Wei-Hu Fan, Shengjia Sun, Haiming Shi, Jian-Feng Luo, Wei Shen, Yufei Chen
Rok vydání: 2020
Předmět:
Adult
Male
China
Acute coronary syndrome
medicine.medical_specialty
Cardiotonic Agents
medicine.medical_treatment
Myocardial Infarction
0211 other engineering and technologies
Placebo-controlled study
02 engineering and technology
030226 pharmacology & pharmacy
Placebos
03 medical and health sciences
Percutaneous Coronary Intervention
0302 clinical medicine
Internal medicine
021105 building & construction
medicine
Humans
Pharmacology (medical)
cardiovascular diseases
Myocardial infarction
Acute Coronary Syndrome
Aged
Plant Extracts
business.industry
Incidence (epidemiology)
Percutaneous coronary intervention
General Medicine
Middle Aged
medicine.disease
Clinical trial
Treatment Outcome
surgical procedures
operative
Complementary and alternative medicine
Elective Surgical Procedures
Conventional PCI
Cardiology
Female
business
Nste acs
Zdroj: Chinese Journal of Integrative Medicine. 26:656-662
ISSN: 1993-0402
1672-0415
1800-0169
DOI: 10.1007/s11655-020-2728-0
Popis: To evaluate the protective effects of salvianolate on percutaneous coronary intervention (PCI) related myocardial injury or myocardial infarction after elective PCI in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients. A total of 149 patients with NSTE-ACS who underwent elective PCI were enrolled. The patients were randomly allocated in a 1:1 ratio to the salvianolate group (74 cases) or the control group (75 cases). After exclusion criteria of coronary angiography, 60 patients with PCI therapy remained in the salvianolate group and 68 in the control group. The incidence and the severity of PCI related myocardial injury or myocardial infarction, in addition to major adverse cardiac events (MACEs) during 1 year follow-up after PCI were studied between the two groups. Multivariate logistic regression analysis was used to determine the independent factors for PCI related myocardial injury or myocardial infarction after elective PCI. Compared with the control group, salvianolate treatment reduced the incidence of PCI related severe myocardial injury or myocardial infarction (11.7% vs. 26.5%, P=0.035). The rate of MACEs or all-cause death within 1 month or 1 year after the procedure was not significantly different between the two groups. Conclusions: Periprocedural treatment with salvianolate reduces the incidence of PCI related severe myocardial injury or myocardial infarction, although it does not influence clinical prognosis. [Chinese clinical trial registry: ChiCTR1800016992]
Databáze: OpenAIRE
Externí odkaz: